These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 16140943)

  • 21. The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer.
    Klenova EM; Morse HC; Ohlsson R; Lobanenkov VV
    Semin Cancer Biol; 2002 Oct; 12(5):399-414. PubMed ID: 12191639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CTCF and BORIS regulate Rb2/p130 gene transcription: a novel mechanism and a new paradigm for understanding the biology of lung cancer.
    Fiorentino FP; Macaluso M; Miranda F; Montanari M; Russo A; Bagella L; Giordano A
    Mol Cancer Res; 2011 Feb; 9(2):225-33. PubMed ID: 21325284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternative promoters of gene MAGE4a.
    De Plaen E; Naerhuyzen B; De Smet C; Szikora JP; Boon T
    Genomics; 1997 Mar; 40(2):305-13. PubMed ID: 9119398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative analyses of CTCF and BORIS occupancies uncover two distinct classes of CTCF binding genomic regions.
    Pugacheva EM; Rivero-Hinojosa S; Espinoza CA; Méndez-Catalá CF; Kang S; Suzuki T; Kosaka-Suzuki N; Robinson S; Nagarajan V; Ye Z; Boukaba A; Rasko JE; Strunnikov AV; Loukinov D; Ren B; Lobanenkov VV
    Genome Biol; 2015 Aug; 16(1):161. PubMed ID: 26268681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer.
    Bhan S; Negi SS; Shao C; Glazer CA; Chuang A; Gaykalova DA; Sun W; Sidransky D; Ha PK; Califano JA
    Clin Cancer Res; 2011 Jul; 17(13):4267-76. PubMed ID: 21558405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
    Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
    J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.
    Link PA; Zhang W; Odunsi K; Karpf AR
    Cancer Immun; 2013; 13():6. PubMed ID: 23390377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas.
    Hines WC; Bazarov AV; Mukhopadhyay R; Yaswen P
    PLoS One; 2010 Mar; 5(3):e9738. PubMed ID: 20305816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region.
    Nguyen P; Cui H; Bisht KS; Sun L; Patel K; Lee RS; Kugoh H; Oshimura M; Feinberg AP; Gius D
    Cancer Res; 2008 Jul; 68(14):5546-51. PubMed ID: 18632606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter.
    De Smet C; Lurquin C; Lethé B; Martelange V; Boon T
    Mol Cell Biol; 1999 Nov; 19(11):7327-35. PubMed ID: 10523621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.
    Magdinier F; Wolffe AP
    Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4990-5. PubMed ID: 11309512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
    Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
    Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CTCF and BORIS in genome regulation and cancer.
    Marshall AD; Bailey CG; Rasko JE
    Curr Opin Genet Dev; 2014 Feb; 24():8-15. PubMed ID: 24657531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovering a binary CTCF code with a little help from BORIS.
    Lobanenkov VV; Zentner GE
    Nucleus; 2018 Jan; 9(1):33-41. PubMed ID: 29077515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines.
    Woloszynska-Read A; James SR; Song C; Jin B; Odunsi K; Karpf AR
    Cancer Immun; 2010 Jul; 10():6. PubMed ID: 20649179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells.
    Law AY; Lai KP; Ip CK; Wong AS; Wagner GF; Wong CK
    Exp Cell Res; 2008 May; 314(8):1823-30. PubMed ID: 18394600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective apoptosis of breast cancer cells by siRNA targeting of BORIS.
    Dougherty CJ; Ichim TE; Liu L; Reznik G; Min WP; Ghochikyan A; Agadjanyan MG; Reznik BN
    Biochem Biophys Res Commun; 2008 May; 370(1):109-12. PubMed ID: 18355444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine.
    Liang G; Gonzales FA; Jones PA; Orntoft TF; Thykjaer T
    Cancer Res; 2002 Feb; 62(4):961-6. PubMed ID: 11861364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of novel target genes by an epigenetic reactivation screen of renal cancer.
    Ibanez de Caceres I; Dulaimi E; Hoffman AM; Al-Saleem T; Uzzo RG; Cairns P
    Cancer Res; 2006 May; 66(10):5021-8. PubMed ID: 16707423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
    Hoivik EA; Kusonmano K; Halle MK; Berg A; Wik E; Werner HM; Petersen K; Oyan AM; Kalland KH; Krakstad C; Trovik J; Widschwendter M; Salvesen HB
    Oncotarget; 2014 Feb; 5(4):1052-61. PubMed ID: 24658009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.